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Alterations in glucose metabolism are associated not only with diseases such as 
Diabetes Mellitus (DM) type 1 and 2 (T1DM and T2DM, respectively) but also with 
neurodegenerative disorders such as Alzheimer’s Disease (AD) and other dementias.  
Transthyretin (TTR), a 55 kDa homotetrameric protein known for its role in transport of 
T4 and retinol, has also been reported to be altered in metabolic disorders. For instance, in 
T2DM and in Gestational Diabetes Mellitus (GDM) TTR is elevated, whereas in T1DM TTR is 
decreased. TTR was also found to promote insulin release to protect against β-cell death and 
to bind to glucose-regulated proteins, to regulate glucagon, recovery of glucose levels, 
suggesting that TTR may play important roles in glucose homeostasis by regulating the 
expression of glucagon. Moreover, TTR, which is also decreased in CSF and plasma of AD 
patients, is the major Aβ peptide sequestering protein in CSF avoiding Aβ aggregation and 
toxicity and thus known to be protective in AD.  
Therefore, this project aimed to investigate the role of TTR in glucose metabolism and 
the implications it might have in AD.  
Here, we showed, using both in vivo and in vitro models, that TTR is involved in glucose 
metabolism at the periphery and at the BBB, since TTR influences the internalization of 
glucose, through 1) the modulation of upstream proteins in the liver, such as glucose 
transporters and possibly 2) the modulation of downstream pathways in the BBB. 
We began by evaluating the effect of TTR in glucose metabolism, by measuring the 
glucose levels in plasma from mice with different TTR genetic backgrounds (with two copies 
of the TTR gene: TTR+/+; with only one copy of the TTR gene: TTR+/-; and without TTR: TTR-
/-). Our results suggested that insufficient amount of TTR impairs uptake of glucose from blood, 
since mice with insufficient TTR (TTR+/- mice) had significantly higher plasma glucose levels, 
although, and confirming the results obtained by another group, plasma glucose levels were 
not altered in TTR-/- animals, as compared to TTR+/+.  
Given the importance of the liver both in glucose homesotasis and in TTR production 
and catabolism, we also evaluated glucose in the culture media of hepatocytes, using both an 
hepatoma cell line (HepG2 cells) and, aiming at bringing the model closer to the in vivo 
situation, primary hepatocytes derived from TTR+/+, TTR+/- and TTR-/- mice. As for the HepG2 
cells, no alterations in glucose levels in their culture media were observed, when cells were 
incubated with human recombinant TTR (hTTR). In relation to the primary hepatocytes, 
interestingly, the results confirmed the observations in the plasmas, as TTR+/− hepatocytes 
presented the highest glucose levels. Importantly, addition of hTTR in the media of TTR+/− 
hepatocytes partially rescued the phenotype and significantly decreased the glucose levels. 
We also observed that glucose in the supernatants of TTR−/− hepatocytes was higher than in 
the TTR+/+, differently from the measurements in plasmas, but still not as high as in the TTR 
+/− supernatants.  
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Given the extreme importance of glucose metabolism in the brain and the related 
alterations in several disorders, we also performed a similar study at the BBB, using the 
hCMEC/D3 cell line, demonstrating that the presence of TTR decreased the glucose levels in 
supernatant media of these cells too. 
To further understand if the observed decreased glucose metabolism was a 
consequence or a cause of the TTR insufficiency in mice, we evaluated the effect of different 
concentrations of glucose in TTR levels. We observed no differences in TTR expression, which 
suggests that glucose alterations do not precede TTR insufficiency, but instead it is the other 
way around: alterations in TTR are prior to the changes in glucose levels. 
Next, we decided to investigate the mechanism behind the observed glucose levels, by 
analyzing the effect of TTR on glucose transporters, namely GLUT1, by immunocytochemistry. 
Here, we observed that in the liver cellular models, but not in our BBB model, TTR increased 
the expression of GLUT1, suggesting that TTR modulates the upstream proteins in glucose 
metabolism at the liver.  
In order to address the impact of TTR in glucose signaling cascade, we then evaluated 
the effect of TTR in the expression of PKM1/2 (at the transcript level) by qRT-PCR and, 
although not statistically significant, we observed increased expression of this gene in the 
presence of TTR in hCMEC/D3 cells, but not in HepG2 cells, suggesting a downstream 
modulation of TTR in glucose signaling pathways in our BBB model. 
Overall, our results suggest that TTR might have a protective role in glucose metabolism, 
although by modulating through different pathways at the BBB and at the liver.  
 
Keywords: Alzheimer’s Disease, Amyloid β peptide, Glucose metabolism, Blood-brain barrier, 
Periphery, Transthyretin.  
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Alterações no metabolismo da glicose estão associadas não só com doenças como a 
Diabetes Mellitus tipo 1 e 2 (DMT1 e DMT2, respetivamente), mas também com doenças 
neurodegenerativas, como a Doença de Alzheimer (DA) e outras demências. 
A transtirretina (TTR), uma proteína homotetramérica de 55 kDa, conhecida pelo seu 
papel no transporte de T4 e retinol, encontra-se alterada em diversas desordens metabólicas. 
Por exemplo, na Diabetes Mellitus, a TTR é encontrada em níveis mais elevados na DMT2 e 
na Diabetes Mellitus Gestacional (DMG), enquanto que na DMT1 se encontra em níveis mais 
baixos. Também foi demonstrado que a TTR pode promover a liberação de insulina, de forma 
a proteger as células β da apoptose, bem como ligar-se a proteínas reguladoras da glicose, 
regular o glucagon e recuperar os níveis de glicose, o que sugere que a TTR desempenha 
importantes funções na homeostase da glicose através da regulação do glucagon.  
Além disso, a TTR, que se encontra diminuída no fluido cérebroespinal e plasma de 
pacientes com DA, é a principal proteína sequestradora do péptido Aβ no fluido 
cérebroespinal, evitando a toxicidade e agregação do Aβ e, portanto, contribuindo para a sua 
função neuroprotetora na DA. 
Portanto, este projeto teve como objetivo investigar o papel da TTR no metabolismo da 
glicose e as implicações que isso possa ter na DA. 
No nosso trabalho, demonstramos, usando modelos in vivo e in vitro, que a TTR está 
envolvida no metabolismo da glicose e modula tanto a barreira hematoencefálica (BHE) como 
a periferia, uma vez que 1) influencia a internalização da glicose, através da 2) modulação 
das proteínas a montante no fígado, tais como os transportadores da glucose e, 
possivelmente, na 3) modulação das vias a jusante no BHE. 
Em primeiro lugar, começou-se por avaliar o efeito da TTR no metabolismo da glicose 
através da medição dos níveis de glucose em plasma de ratos com diferentes backgrounds 
genéticos de TTR (com duas cópias do gene da TTR: TTR+/+; com apenas uma cópia do 
gene da TTR: TTR+/-; e sem TTR: TTR-/-). Estes resultados sugeriram que a insuficiência de 
TTR prejudica a captação de glicose do sangue, uma vez que os ratos com insuficiência de 
TTR (ratos TTR+/-) apresentaram níveis plasmáticos de glicose significativamente maiores, 
embora, e confirmando os resultados obtidos por outro grupo, os níveis de glicose no plasma 
não se alteraram nos animais TTR-/-, comparativamente aos TTR+/+.  
Dada a importância do fígado não só na homeostase da glicose, como também na 
produção e catabolismo da TTR, também avaliamos a glicose nos meios de cultura de 
hepatócitos, utilizando uma linha celular de hepatomas (células HepG2) e hepatócitos 
primários derivados de ratos TTR+/+, TTR+/- e TTR-/-, visando aproximar o modelo da 
situação in vivo. Relativamente às células HepG2, não se verificaram alterações nos níveis de 
glicose no seu meio de cultura, quando incubadas com TTR humana recombinante (hTTR). 
Quanto aos hepatócitos primários, curiosamente, confirmou as observações obtidas nos 
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plasmas, sendo que os hepatócitos TTR+/- apresentaram on níveis de glicose mais elevados. 
De salientar que, a adição de hTTR no meio dos hepatócitos TTR-/- levou a uma recuperação 
parcial do fenótipo e a um decréscimo significativo dos níveis de glicose. Também observamos 
que os níveis de glicose nos sobrenadantes dos hepatócitos TTR-/- eram mais elevados que 
dos TTR+/+, diferente das medições observadas nos plasmas, mas ainda assim não tão 
elevado como nos TTR+/-. 
Dada a extrema importância do metabolismo de glicose no cérebro e alterações que 
neste ocorrem relacionadas com diversos distúrbios, também realizamos um estudo 
semelhantes na BHE, utilizando a linha celular hCMEC/D3, demonstrando que, na presença 
de TTR, os níveis de glicose diminuem no subernadante destas células. 
Para entender melhor se a diminuição do metabolismo da glicose seria uma 
consequência ou uma causa da insuficiência de TTR nos ratos, avaliamos o efeito de 
diferentes concentrações de glicose nos níveis da TTR. Aqui, não foram observadas 
diferenças na expressão de TTR, o que sugere que as alterações na glicose não precedem a 
insuficiência de TTR, mas em vez disso o oposto, ou seja, alterações na TTR são anteriores 
às mudanças nos níveis de glicose. 
Em seguida, investigou-se o mecanismo responsável pelos níveis de glicose, através 
da análise do efeito da TTR nos transportadores da glicose, principalmente o GLUT1, por 
imunocitoquímica. Aqui, observou-se que nos modelos celulares de fígado, mas não no 
modelo da BHE, a TTR aumenta a expressão do GLUT1, o que sugere que a TTR modula as 
proteínas ascendentes do metabolismo da glucose, no fígado.  
Assim, de forma a avaliar o impacto da TTR na cascata de sinalização da glicose, 
avaliou-se o efeito da TTR na expressão do gene PKM1/2 (ao nível da transcrição), através 
da execução de um qRT-PCR e, embora não estatisticamente significativo, observamos um 
aumento na expressão deste gene na presença de TTR nas hCMEC/D3, mas não nas células 
HepG2, sugerindo uma modulação descendente, por parte da TTR, nas vias de sinalização da 
glicose no nosso modelo de BHE. 
De um modo geral, os nossos resultados sugerem que a TTR pode desempenhar um 
papel protetor no metabolismo da glucose, embora modulando diferentes vias ao nível da BHE 
e do fígado. 
Palavras-chave: Doença de Alzheimer, Péptido β-amiloide, Metabolismo da Glicose, Barreira 
hematoencefálica, Periferia, Transtirretina. 
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Research Project – Abbreviations FMUP/i3S-IBMC 
 
22 
 
KO   Knockout 
LRP1   Low-density lipoprotein receptor-related protein 1 
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MHC   Major histocompatibility complex 
MODY  Maturity onset diabetes of the young 
NCBI   National center of biotechnology information 
NEP   Neprilysin 
NPY   Neuropeptide Y 
NTF   Neurofibrillary tangles 
O/N   Overnight 
PBS   Phosphate-buffered saline 
PBS-T  Phosphate-buffered saline Tween-20 
PHF   Paired helical filaments 
PI3K   Phosphoinositide 3-kinase 
PKM1/2  Pyruvate kinase M1/2 isoforms 
PM  Plasma Membrane 
PMSF   Phenylmethylsulfonyl fluoride  
PNS   Peripheral Nervous System
PSEN 1  Presenilin 1  
PSEN 2  Presenilin 2 
PVDF   Polyvinylidene fluoride 
qRT-PCR  Real-time polymerase chain reaction 
RAGE   Receptor for advanced glycation end products 
RBP   Retinol binding protein 
RT   Room temperature 
sAPPα  Soluble amyloid-beta precursor protein alpha 
Research Project – Abbreviations FMUP/i3S-IBMC 
 
23 
 
SLGT   Sodium-linked glucose transporters 
SP   Senile plaques 
SSA   Senile system amyloidosis 
TH   Thyroid hormone 
Tg   Transgenic 
TTR   Transthyretin 
T4   Thyroxine 
T1DM   Type 1 Diabetes Mellitus 
T2DM   Type 2 Diabetes Mellitus 
UDP   Uridine diphosphate glucose 
WB  Western Blot 
WE   William’s E medium 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
  
Research Project – Introduction FMUP/i3S-IBMC 
 
25 
 
1. Energy metabolism 
 
Our body requires energy to function properly, especially the brain, a very complex 
structure, that requires high amounts of energy that provides it sensitive to changes in energy 
fuel supply and mitochondrial function. This complex structure utilizes 25%, approximately, of 
the total body glucose, and the majority of which is used to transduce energy through glycolysis 
and mitochondrial oxidative phosphorylation to support synaptic transmission (Yin et al., 2016). 
This energy provided by glucose consumption, through food intake, is possible by the 
liver function, a crucial organ that is responsible for the maintenance of normal glucose 
homeostasis, which means that it produces glucose during fasting – glycogenolysis and 
gluconeogenesis (Aronoff et al., 2004) - and stores it postprandially. 
Circulating glucose is derived from three sources: intestinal absorption during the fed 
state, where there’s a gastric emptying; glycogenolysis and gluconeogenesis, which are 
hepatic processes (Aronoff et al., 2004). 
 
1.1. Liver glucose metabolism 
 
The liver is a complex organ comprising multiple different functions. It acts as a factory, 
being responsible for body energy metabolism, namely through the metabolism of proteins, 
carbohydrates, lipids, iron, copper, and acts also as a detoxifier (Sendensky, 2011). Regarding 
glucose metabolism, hepatocytes are the main cell type in the liver, where blood glucose enters 
through glucose transporter 2 (GLUT2) and is then released through other transporters or even 
other mechanisms (Rui, 2014). In the fasting state, the synthesis of glucose in the liver, de 
novo, from precursors such as lactate, gluconeogenic amino acids and glycerol 
(gluconeogenesis) is important to provide the organism with glucose. In the feeding state, 
when glucose is already available, gluconeogenesis must be inhibit (Barthel & Schmoll, 2003). 
These mechanisms together result in a net of hepatic glucose production (HGP). 
 
1.1.1. Glycogen metabolism 
 
The glycogen metabolism is important both in the fed and fasted states, as previously 
mentioned, but mainly after a meal, in which glucose is converted to glycogen, in order to 
remove glucose from the portal vein (Agius, 2008), as well as providing a storage form of 
glucose that can be used in the fasted state (Han et al., 2016). The main precursor for glycogen 
synthesis is glucose-6-phosphate (G6P), that results from the phosphorylation, by glucokinase 
(GK), of glucose that was up taken from circulation via GLUT2 (Rui, 2014). Then, the G6P is 
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Figure 1 -  Mechanisms of glucose regulation (Roden & Bernroider 2003). 
transformed into glucose-1-phosphate (G1P) by phosphoglucomutase, that is subsequently 
converted into UDP-glucose by UDP-glucose phosphorylase (UGP) and, finally, glycogen 
synthase converts it into glycogen, that is stored post-prandial (Adeva-Andany et al., 2016). 
The amount of glycogen formed is determined by the amount of glucose uptake, as well as by 
the amount of glycogen already present (Radziuk & Pye, 2001) and the accumulation of this 
glycogen in the liver during the fed state provides storage of glucose used in the fasting state 
(Han et al., 2016). 
 
1.1.2. Gluconeogenesis 
 
Gluconeogenesis is the de novo glucose synthesis under long periods of fasting or 
starvation (Han et al., 2016), using as main sources lactate, amino acids and glycerol (Barthel 
& Schmoll, 2003), which are generated in the liver or delivered to the liver through the 
circulation from extrahepatic tissues (Rui, 2014) (Figure 1).  
 
 
 
 
 
 
 
 
1.2. Normal physiology of insulin secretion and action 
1.2.1. Insulin structure and function 
 
Insulin was first described as a result of a collaboration between the surgeon Frederick 
G. Banting and his students assistant, winning the Nobel Prize for Physiology or Medicine 
(Bilous & Donnelly, 2010).  
Insulin is molecule formed by two polypeptide chains linked by disulphide bridges and it 
is found, in circulation, as a monomer with a molecular weight of 6 kDa. This hormone, 
discovered more than 75 years ago (Shepherd & Kahn, 1999b) is the most important, as well 
as the only β-cell hormone known to lower blood glucose concentrations (Aronoff et al., 2004). 
Firstly, it is synthetized as a larger precursor, preproinsulin, which is cleaved by protease 
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Figure 2 - Biosynthesis and processing of insulin (Bilous & Donnelly 2010). 
 
activity, prohormone convertases (Rutter et al., 2015), to proinsulin, which is then stored in 
vesicles in the Golgi of β-cell. Still, in an early stage of development, in the secretory granules, 
this proinsulin is converted into insulin and C-peptide (Figure 2), that are then released by 
exocytosis, when the granules are transported to the cell surface, being the actin cytoskeleton 
and cyclic GTPases mediators of the biphasic insulin release (Bilous & Donnelly, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding insulin functions, insulin, among a group of other hormones (glucagon, GLP-
1, cortisol, growth hormone), is known to control the glycogenolysis and gluconeogenesis, in 
order to maintain circulating glucose within normal concentrations (Petersen et al., 2017). 
Besides that, it is also responsible for glucose and fat uptake through triggering the 
translocation of the intracellular glucose transporter GLUT4 to the plasma membrane (Ward, 
2015); stimulating the storage of glycogen and nucleic acids (fat) in the liver, muscle and 
adipocyte tissue (Saltiel & Kahn, 2001), through the stimulation of glycogenesis, lipogenesis 
(increased activation and phosphorylation of acetyl-coA carboxylase (Wilcox, 2005); and 
reducing glucose production and release by the liver through glycogenolysis (Ward, 2015), 
whenever there’s an excess of glucose in the blood circulation. 
 
1.2.2. Insulin secretion and regulation 
 
For the proper function of insulin response, β-cell have to function properly, because 
their sensitivity to glucose is determined by the peripheral tissues’ sensitivity to insulin action 
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Figure 3 - Phases of insulin secretory responses over time (Pratley & Weyer 2001). 
Figure 3 
 
 
Figure 4 - Glucose-insulin dose-response (Bilous & Donnelly 2010). 
(Bell & Polonsky, 2001). Synthesis and secretion of insulin is regulated by both nutrient and 
non-nutrient secretagogues, regarding environmental stimuli and the interplay of other 
hormones (Figure 3). The nutrient secretagogues that trigger insulin are mainly glucose; the 
non-nutrient secretagogues act through neural stimuli, namely cholinergic and adrenergic 
pathways or peptide hormones, for example, GLP-1, or even cationic amino acids (Wilcox, 
2005). 
 
 
 
 
 
 
 
 
This glucose-insulin dose-response (Figure 4), in response to a dose stimulation of 
about 8 mmol/L of glucose, is primarily determined by the activity of glucokinase, which is 
expressed in higher levels in the pancreatic β-cell and the liver (Bell & Polonsky, 2001). 
On one hand, in the β-cells, once glucose enters via GLUT2, the glucokinase acts as a 
sensor of glucose, controlling glucose entry into the glycolytic pathway and its metabolism, 
which further triggers the release of insulin into the circulation (Bilous & Donnelly, 2010). The 
latter mechanism may be activated through hormones. 
On the other hand, in the liver the glucokinase, stores glucose as glycogen, particularly 
in the postprandial state (Bell & Polonsky, 2001), in other words after eating a meal. 
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Besides the response of insulin to ingestion of glucose, there is also the incretin effect, 
which are two hormones: glucagon-like peptide-1 (GLP-1), secreted by L cells, and gastric 
inhibitory polypeptide (GIP), secreted by K cells of the upper jejunum wall (Bilous & Donnelly, 
2010) responsible for insulin release in the GI tract (Wilcox, 2005). The GLP-1 is also 
responsible for the inhibition of glucagon release, delays in the gastric emptying and reduction 
of appetite. 
Moreover, other genes involved in insulin secretion are HNF-1α, HNF-1β and HNF-4α, 
that are transcription factors that control gene expression during the embryonic development 
and in adults tissues, and that are also involved in glucose transport, glycolysis and 
mitochondrial metabolism (Bell & Polonsky, 2001). 
 
1.2.3. Insulin receptors and binding 
 
For insulin act properly, it needs to bind to insulin receptors. The insulin receptor (IR) has 
two α and two β glycoprotein subunits and insulin binds to the extracellular α subunit, 
generating ATP, which binds to the intracellular β subunit and phosphorylates it, conferring 
tyrosine kinase activity and, subsequently, insulin responsive substrates (IRS). These IRS, 
which then bind to other signaling molecules mediating further cellular actions of insulin. There 
are four known IRS proteins: IRS-1, IRS-2, IRS-3 and IRS-4. The first two, which are the most 
well characterized, are mainly in the skeletal muscle and liver, respectively, and IRS-1 
mediates mitogenic effects of insulin and is the ligand for glucose sensing to insulin, whereas 
the IRS-2 mediates insulin peripheral actions and growth of β-cells (Wilcox, 2005). 
 
1.2.4. Glucose transporters (GLUTs) 
 
In order to organs to be supplied with glucose, systems of transport are required for 
maximal glucose transport, and these are the cellular transporters of glucose: the GLUTs and 
sodium-linked glucose transporters (SLGT), which are restricted to the intestine and kidney, 
transporting glucose against a glucose-concentrations gradient by using, as an energy source, 
sodium cotransport (Shepherd & Kahn, 1999a). The types of GLUTs which are best 
characterized are: GLUT1, GLUT2, GLUT3, GLUT4, GLUT5, GLUT8, GLUT9, GLUT10 and 
they all have distinct substrate specificities, kinetic properties and tissues distributions that 
determine their functions (Bilous & Donnelly, 2010; Shepherd & Kahn, 1999b). Among them, 
GLUT1 to 4, which belong to the class I, are the most important in the transport of glucose 
(Navale & Paranjape, 2016) (Table 1). 
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Table 1. Summary of the properties of the glucose transporters (Bilous & Donnelly, 2010; Shepherd & Kahn, 1999b; 
Zhao & Keating, 2007). 
Protein Site of expression Function 
GLUT1 Ubiquitously expressed in tissues and 
cultured cells 
Mediates basal and non-insulin mediated 
glucose uptake 
GLUT2 Islet β-cells, liver, intestine, kidneys Glucose sensor, together with glucokinase, 
being a high-capacity low-affinity transport 
GLUT3 Brain and nerve cells Non-insulin mediated glucose uptake to the 
brain  
GLUT4 Muscle, adipose tissue, heart Insulin-stimulated glucose uptake 
 
The main insulin-responsive glucose transporter is GLUT4, that is also known to have 
interactions with GLUT1, in adipose tissue and muscle. During insulin signaling, the vesicles 
at the basal state, where GLUT4 is, are translocated to the plasma membrane, where they 
fuse with GLUT1 allowing glucose to enter the cell (Bilous & Donnelly, 2010; Zhao & Keating, 
2007). This process is reversible, being the vesicles with GLUT4 recycled.  
Regarding the central nervous system (CNS), the most studied transporter is GLUT1, 
due to the fact that it is one of the major transporters in supplying brain cells with glucose. 
Despite of the many studies until now, little is known about the structure and mechanism of 
GLUT1.  
In the peripheral nervous system (PNS), the most studied transporter is GLUT4, since it 
is directly involved in the trafficking of proteins, cellular components, related with insulin in 
order to maintain body glucose homeostasis. A dysregulation at these levels can lead to 
obesity and type 2 diabetes, although the underlying mechanism is still poorly understood 
(Thorens, 2014).  
The liver was recognized to play a predominant and important role in the disposal of 
meal glucose, regarding its position between the portal circulation draining the gut and the 
systemic circulation acting as a filter (Radziuk & Pye, 2001). In the liver, the main cell type are 
the hepatocytes, as previously mentioned, and in these cells GLUT2 is the predominant 
hepatic glucose transporter in humans, through which blood glucose enters, but also facilitates 
glucose release to the bloodstream, whereas in the pancreas GLUT2 contributes to glucose-
mediated insulin secretion (Adeva-Andany et al., 2016)   
Importantly, the regulation of these transporters before and after the beginning of 
lactation indicates that their expression and function is mainly regulated by hormonal changes 
(Zhao & Keating, 2007). 
Overall, in normal subjects, these proteins, together with other mechanisms, maintain 
the glucose homeostasis, allowing a balance between the glucose released from the liver and 
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intestine into the blood circulation and the glucose uptake into the peripheral tissues (muscle 
and adipose tissue), which, therefore, maintain insulin at lowers levels in the fasting state and 
at higher levels at mealtimes (Bilous & Donnelly, 2010).  
  
1.3. Liver and brain crosstalk 
 
The liver’s metabolism is regulated by the CNS via sympathetic nervous system, which 
promotes HGP and mobilization of metabolic fuels for extrahepatic tissues, and 
parasympathetic nervous system, which suppresses sympathetic nervous system action and 
inhibits HGP, but also promotes fuel storage in the liver (Rui, 2014).  
As previously described, insulin has direct effects on the liver by inhibiting 
glycogenolysis, but it also has indirect effects mainly through the activation of hypothalamic 
insulin signaling, which includes the modulation of feeding behavior, neuropeptide Y 
expression, hypoglycemia counter-regulation and autonomic outflow, in order to regulate 
glucose production (Puglianiello & Cianfarani, 2006). Importantly this suppression of HGP is 
possible through the hyperpolarization of neurons due KATP channel activation (Inoue, 2016), 
involving the insulin receptor, IRS and PI3K (Puglianiello & Cianfarani, 2006). This input relays 
to the motor nucleus of the vagus nerve in the brainstem, leading to the activation of efferent 
vagal fibers, which innervate the liver (Pocai et al., 2005). 
Moreover, leptin, another circulating hormone, also plays a role in glucose homeostasis, 
through the stimulation of melanocortin-independent pathways involving insulin-like pathways, 
such as PI3K signaling cascade (Puglianiello & Cianfarani, 2006). 
Overall, this crosstalk is important for the body’s metabolic and nutritional status because 
CNS has a major role in the control of insulin sensitivity and glucose homeostasis. An onset 
hypothalamic resistance to multiple signs can contribute to the susceptibility of insulin 
resistance, which means that diabetes can be a disorder with underlying CNS defects 
(Puglianiello & Cianfarani, 2006).  
 
2. Diabetes Mellitus (DM) 
 
Diabetes was first described by Aretaeus in the second century, but the adjective Mellitus 
was introduced by John Rollo (d. 1809). The knowledge on Diabetes Mellitus (DM) had many 
contributors, besides the ones mentioned, and Claude Bernard and Paul Langerhans were 
also involved (Bilous & Donnelly, 2010). DM consists of a metabolic disorder that comprises 
multiple etiologies (Figure 5) and affects about 30.3 million people worldwide at all ages, but 
with great incidence in the older people (for Disease Control, Prevention, and others 2017). 
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Figure 5 - Characterization of diabetes (Ize-Ludlow & Sperling, 2005). 
According to WHO and American Diabetes Association, DM presents a variety of symptoms, 
due to the fact that it presents several pathogenic processes comprising a range from 
autoimmune destruction of the pancreatic β-cells to abnormal insulin action (American 
Diabetes Association, 2004). Since its prevalence is increasing drastically, the WHO estimates 
that by 2030 there will be 370 million adults with diabetes, almost the double from today’s 
number (Ozougwu, 2013), which is concerning given the long-term consequences that patients 
can suffer, namely blindness, kidney dysfunction, cardiovascular disease, which are the 
principal cause of morbidity and mortality (Alkayyali & Lyssenko, 2014). In Europe, about 6-
8% of the population suffers from diabetes and 90% of them has Type 2 Diabetes Mellitus 
(T2DM) and 10% Type 1 Diabetes Mellitus (T1DM), being T2DM the most common and fastest 
increasing type of diabetes both in Europe and worldwide (Groop & Pociot, 2014). 
The current classification of DM is based on its etiology and there are four categories: 
T1DM, T2DM - which are the most common - gestational diabetes and other specific types of 
diabetes, caused by diseases of the exocrine pancreas, genetic syndromes, and many other 
(Bilous & Donnelly, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1. Genetics 
 
For many years that the knowledge about the role of genetic factors as a risk of DM is 
known, although there is a lack of knowledge about the underlying genes, which is referred as 
missing heritability (Manolio et al., 2009). In 1935, Hinsworth established two types of diabetes 
(Ali, 2013): T1DM, which is characterized by absolute insulin deficiency resulting from 
autoimmune destruction of pancreatic β-cells, and is more common among children and young 
adults (Groop & Pociot, 2014) and T2DM, which is heterogeneous metabolic disorder resulting 
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from decreased sensitivity of tissues to insulin (Pullakhandam et al. 2012), that commonly 
occur in the adulthood, more likely at 65 years old or older (Chatterjee et al., 2017).  
There is a long history of studies regarding the genetics of diabetes, but with the 
development of genome-wide maps, genome sequencing and understanding of human 
population genetics, it was possible to gain knowledge on the underlying mechanism, in a 
population-based manner (Ali, 2013; Florez et al., 2003; Groop & Pociot, 2014). 
On one hand, T1DM is considered as a complex genetic trait, which means is not only 
associated with multiple genetic loci but also with environmental factors. Until now, two 
chromosomal regions are known, namely the human leukocyte antigen (HLA) region, within 
the major histocompatibility complex (MHC) in the chromosome 6p21.3, which provides a 
strong clustered in families of about 40-50% and the insulin gene region in the chromosome 
11p15, being T1DM very specific to pancreatic β-cells, since insulin or insulin precursors may 
act as autoantigens (Groop & Pociot, 2014). Moreover, in T1DM, the risk for monozygotic twins  
is higher (100% concordance) than for dizygotic twins (Florez et al., 2003), due to the 
dependent degree of genetic identity with the proband, among family members (Groop & 
Pociot, 2014). 
On the other hand, T2DM results from an interaction between environmental factors 
(obesity, stress, sedentary lifestyle, age) and a hereditary component of about 20-80%. 
However, this family risk relies on the great impact of the environmental factors, since studies 
indicate that there is a higher risk of developing diabetes later in life. Nevertheless, this risk is 
not only due to genetic factors, but also due to epigenetic processes such as intrauterine and 
pregnancy (Ali, 2013), which can give rise to Gestational Diabetes Mellitus (GDM), 
characterized by glucose intolerance during pregnancy (Chen et al., 2017). Despite that, the 
genetic risks of T2DM are not completely defined, but it known that the monogenic diabetes of 
the young (MODY) can be caused by mutations in the hepatocyte nuclear factor-1A (HNF1A) 
and in the glucokinase gene (GCK) (Ali, 2013).  
Overall, there’s evidence that genetics are implicated in T1DM and T2DM, although the 
genetic contribution differs for each, being the genetic risk for T1DM greater than for T2DM, 
as well as the genes involved in both (Rich, 2006). 
 
2.2. Pathophysiology 
2.2.1. Pancreatic β-cells decline and insulin dysfunction 
 
As previously described, the pancreatic β-cells are crucial for the normal response to 
insulin resistance by increasing their output of insulin according to the tissues needs. However, 
the decline of the function of these cells can include cytokine-induced inflammation (oxidative 
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Figure 6 - Phasic insulin response in non-diabetic and diabetic patients (Skyler, 2004). 
stress, endoplasmic reticulum stress, inflammation), obesity, overconsumption of saturated fat 
and free fatty acids (FFA), and insulin resistance, which is a hallmark of T2DM. Both T1DM 
and T2DM have loss of β-cell and of its functions (Cerf, 2013). 
In T2DM, the initial manifestation of the abnormal insulin secretion is the loss of the first-
phase, the fasting state, because of increased hepatic glucose production which explains the 
occurrence of hyperglycemia (Skyler, 2004), as well as hyperinsulinemia (Aronoff et al., 2004), 
(Figure 6). Besides, it is also observed a delayed response of insulin, as well as abnormal 
oscillations of insulin release throughout the day (Bilous & Donnelly, 2010). The initiating 
mechanisms that can cause this impairment are proposed to be the activation of FOXO1 in the 
liver and the disruption of GLUT4 translocation in the muscle (Czech, 2017). Moreover, 
elevated levels of serum retinol-binding protein 4 (RBP4) cause insulin resistance and impair 
insulin signaling.  (Zemany et al., 2015) 
Furthermore, amyloid deposits in the pancreatic islets is also considered to be a 
pathological characteristic of T2DM, since it is known that it limits the glucose-stimulated insulin 
secretion, although this mechanism is not fully understood (Cernea & Dobreanu, 2013). 
T2DM has, in fact, many metabolic abnormalities and despite the main mechanism 
remaining poorly unknown, it is known that this disease leads to microvascular complications 
that affect many organs, namely the brain. 
 
 
 
 
 
 
 
 
 
2.2.2. Brain metabolism impairments 
 
In individuals with T2DM, the rate of hepatic glucose production (HGP) is increased 
under basal physiological conditions and insulin-dependent suppression of HGP is impaired, 
which represents hepatic insulin resistance (Petersen et al., 2017), at the brain level and 
periphery (Li et al., 2015), since insulin acts in multiple brain regions influencing many 
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pathways, such as regulation of food intake, neuronal growth, differentiation by regulating 
neurotransmitter (Das, 2002). 
This impaired function of insulin alters glucose homeostasis in the brain, consequently, 
impacting energy metabolism, which can lead to a cognitive decline, that affects the brain 
through several mechanisms that include, for example, glucotoxicity and lipotoxiciy, that affect 
the vasculature of the brain, by impairing synaptic plasticity, as well as the metabolism of 
amyloid-β peptide (Aβ) and Tau protein and, consequently, accelerating cognitive decline 
(learning and memory) and dementia (Duarte, 2015). 
Understanding pathways of glucose metabolism of healthy humans may help to clarify 
metabolic alterations that occur in diabetes mellitus (Adeva-Andany et al., 2016) and also in 
Alzheimer’s Disease (AD), since in this disease, characterized by a decline of the cognitive 
function, metabolic alterations such as insulin resistance and hyperglycemia (Arieta-Cruz et 
al., 2016) also occur. 
 
3. Alzheimer’s Disease (AD) 
 
AD is one of the most common neurodegenerative disease, first described by Dr. Alois 
Alzheimer, and accounts for more than 80% of the dementia cases worldwide in older people, 
usually older than 65 years of age (Kumar et al., 2015). According to Alzheimer’s Association, 
the symptoms of the disease vary among individuals, because, like other common chronic 
diseases, AD develops as a result of multiple factors, being age the major one, rather than a 
single cause. It is expected that by 2050, one new case of AD develops every 33 seconds, 
resulting in nearly 1 million new cases per year (Alzheimer’s Association, 2015). Due to that 
fact, is one of the most intensively studied disease, giving rise to several hypothesis about its 
pathogenesis, for example, Aβ and tau hyperphosphorytation hypothesis, (Chen & Zhong, 
2013) despite until now the etiological mechanisms underlying the neuropathology still remain 
unclear.  
 
3.1. Genetics 
 
The majority of patients only start developing clinical symptoms at age older than 65 
years (late-onset AD), despite 2-10% of them have an earlier onset of disease (early-onset 
AD) or autosomal dominant familial AD (FAD). The search for the genetic factors contributing 
to AD has evolved massively throughout the years, starting with the discovery of mutations 
that are involved as a cause of FAD, namely amyloid precursor protein (APP), presenilin 1 and 
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2 (PSEN1 and PSEN2) (Van Cauwenberghe et al., 2016). Mutations in these genes might 
result in alteration of Aβ production, consequently leading to neuronal death and dementia 
(Bagyinszky et al., 2014) (Figure 7). 
 
 
  
 
Figure 7 - The amyloid precursor (APP), PSEN1 and PSEN2 genes. 
 
In the late-onset AD, the major risk factor is in apoliprotein E (ApoE) gene, but also non 
genetic factors may be involved. ApoE gene is located on chromosome 19q13 that encodes 
three alleles, namely ε2 (8%), ε3 (77%) and ε4 (15%) (Bagyinszky et al., 2014; Karch & Goate 
2015), it is expressed in liver, brain, macrophages and monocytes (Van Cauwenberghe et al., 
2016) and is responsible for the transport and metabolism of lipids (Imbimbo, Lombard, and 
Pomara 2005). Among the three different isoforms, the presence of ApoE ε4 allele increases 
the risk by 12-fold, for AD development. Conversely, the ApoE ε2 is associated with decreased 
risk for AD and later age at onset (Imbimbo et al., 2005; Karch & Goate 2015). 
 
3.2. Pathophysiology 
3.2.1. Neuropathology  
 
Auguste Deter, was the first AD patient and when she was autopsied, changes in the 
brain were observed that, by the time, were associated with dementia and general cortical 
atrophy, but no prior descriptions existed (Stelzmann et al., 1995). Then, when senile dementia 
started to increase in proportion to life expectancy, Kartzman assumed that “AD and senile 
dementia are a single process and should, therefore, be considered a single disease”. In fact, 
structural studies back then, observed neurofibrillary tangles (NTFs) originated from 
intracellular aggregates of hyperphosphorylated tau protein and senile plaques (SP) caused 
by Aβ accumulation and degenerating neurites in the cerebral cortex (Katzman, 1976), besides 
the visible atrophy of the brain, macroscopically (Tomlinson et al., 1970).  
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Figure 8 - Representation of NTFs formation (Mokhtar et al., 2013). 
3.2.1.1. Neurofibrillary tangles 
 
Since the first description of two microscopic structures by Alois Alzheimer in 1907, 
previously mentioned, that senile plaques and neurofibrillary tangles became hallmarks of AD 
(Kumar et al., 2015). The NTFs are fibrils with ~10 nm of diameter that form pairs with helical 
3D conformation, named paired helical filaments (PHFs) (Serrano-Pozo et al., 2011) and are 
composed of the microtubule-associated protein tau (Selkoe, 2001), although other proteins, 
such as, ubiquitin, Aβ, can also be associated to NTFs (Perl, 2010). When tau is 
hyperphosphorylated, it results in a loss of function, resulting in its dissociation from the 
microtubule and, consequently, formation of NTFs, leading to neurons’ apoptosis (Brion & 
Brion, 1998).  
These microscopic structures have been descried to have three distinguished 
morphological stages: pretangle or diffuse NTFs, mostly present in the somatodendritic 
compartment; mature or intraneuronal NTFs, which appear in soma and dendrites (Brion & 
Brion, 1998; Serrano-Pozo et al., 2011); and the extraneuronal, the classical NTFs that can be 
observed in the layer II neurons of the entorhinal cortex, the CA1 and subicular regions of the 
hippocampus, the amygdala, and the deep layers (layers III, V, and superficial IV) of the 
neocortex (Perl, 2010; Selkoe, 2001; Serrano-Pozo et al., 2011) (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
Moreover, AD is not the only disease associated with neuropathological lesion, there are 
many others, namely, Parkinsonism, Pick’s disease, posttraumatic dementia, and many others 
(Armstrong, 2009; K. Iqbal et al., 2010; Perl, 2010). 
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Figure 9 - Representation of microscopic hallmarks of AD. (a) senile plaques; (b) neurofibrillary tangles; (c) 
phosphorylated tau (Bossy-Wetze et al., 2004). 
3.2.1.2. Senile plaques 
 
The other lesion observed in brains of AD patients are the senile plaques (SP) (Figure 
9), also known as neuritic plaques, which are extracellular amyloid deposits, whose chemical 
structure was identified by George Glenner (Sweatt, 2010), but can be also a characteristic of 
aging (Cras et al., 1991; Tomlinson et al., 1970). This plaques, found in cortex and 
hippocampus, have a variable size and morphology, thus being divided in different subtypes, 
such as diffuse SP (pre-amyloid), primitive (neuritic), classic (dense-cored) and compact-type 
(burnt-out) (Armstrong, 2009). Moreover, this plaques are regionally dependent, in other 
words, mostly found in limbic and association cortices, and often associated with microglia 
(Cras et al., 1991; Selkoe, 2001). The dense-cored subtype is associated with increased 
neurite curvature, dystrophic neurites, synaptic loss, neuron loss, and recruitment and 
activation of astrocytes and microglia (Serrano-Pozo et al., 2011). Importantly the main 
component of these structures is Aβ. 
 
 
 
 
 
 
 
3.3. Aβ Biochemistry 
 
As previously mentioned, Aβ is the main component of senile plaques in AD. This small 
peptide, with approximately 4 kDa, is the product of the proteolytic processing of the type I 
transmembrane protein – APP – important for normal brain (Shariati & De Strooper, 2013). 
Glenner and Wong were the first ones to isolate and sequence Aβ, that was found to be present 
also in the serum, brain and CSF (Glenner et al., 1984).  
Since the initial identification of Aβ, that it has been seen as a neurotoxic peptide, but 
not all of its physiological functions have negative effects, for instance, it has been shown to 
be an antimicrobial peptide (D. Kumar et al., 2016), as ion channel modulation for neuronal 
survival (Pearson & Peers, 2006), transcriptional factor and cholesterol transport regulator 
(Nhan, 2015). 
APP is a protein abundant in the brain and there is great genetic evidence that altered 
cellular processing of APP is causative of many diseases (Di Carlo, 2010), namely early onset-
AD with cerebral amyloid angiopathy (Thinakaran & Koo, 2008). APP can be processed 
a b c 
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through two different pathways: nonamyloidogenic and amyloidogenic pathways, producing 
afterwards Aβ peptide (Figure 10). 
 
3.3.1. The APP processing and the production of Aβ: non-amyloidogenic and 
amyloidogenic pathways 
 
The proteolytic processing of APP, by a family of secretases, has two different pathways: 
nonamyloidogenic and amyloidogenic pathways, which results in the release of secreted 
derivatives into vesicle lumens and the extracellular space with different functions (Selkoe, 
2001; Sweatt, 2010).  
In the nonamyloidogenic pathway, that is in the normal physiological conditions, APP is 
cleaved by two enzymes: the α-secretase, an enzyme of ADAM family (Swerdlow, 2007) that 
generates a large soluble fragment (sAPPα), responsible for synaptic plasticity, learning, 
memory, neuronal survival; and the retention of C83 carboxyl-terminal (or αCTF)  (Hernández-
zimbrón et al., 2016). Then, γ-secretase cleaves the C83 resulting in the release of p3 peptide 
(~3 kDa) (Thinakaran & Koo, 2008) and an APP intracellular domain (AICD) fragment.  This 
process prevents the deposition of  β-amyloid in plaques, thus contributing, as previously 
mentioned, to neuronal survival (Hernández-zimbrón et al., 2016).  
On the contrary, in the amyloidogenic pathway, instead of being cleaved by α-secretase, 
APP is cleaved by β-secretase, termed BACE-1, which generates a smaller soluble fragment 
sAPPβ and a retaining 99-residue fragment CTF (C99 – 12 kDA) in the membrane (Imbimbo, 
Lombard, and Pomara 2005; Selkoe 2001). This last fragment is then cleaved by γ-secretase, 
which leads to the production of Aβ peptides (~4 kDa), with 38-43 amino acids (Sweatt, 2010; 
Swerdlow, 2007). Consequently, this Aβ peptides can spontaneously aggregate into soluble 
oligomers and form the amyloid plaques (A. Kumar et al., 2015), which can have a neurotoxic 
effect in the brain, namely disruption of calcium homeostasis, mitochondrial oxidative stress, 
impaired energy metabolism and abnormal glucose regulation and, consequently, neuronal 
death (Cell Signalling, 2009) (Figure 10). However  studies indicate that Aβ peptide is a normal 
metabolic event and it is detected also in CSF and plasma of healthy subjects throughout life 
(Selkoe, 2001), so how does Aβ peptide affect the brain by causing AD?  
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Figure 10 - Amyloid plaque and neurofibrillary tangle formation in AD (Cell Signalling, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2. The amyloid cascade hypothesis 
 
AD still remains one of the most intriguing diseases, since its etiology remains a question 
mark and throughout the years many theories have been developed in order to explain this 
disorder, based in different molecular mechanisms.  
Among these theories, the amyloid cascade hypothesis, formalized by Hardy and 
Higgins (1992), was, and still is, the most influential in the academic and pharmacological 
research (John & Gerald, 1992). This theory postulates that the neurodegeneration in AD is 
caused by abnormal accumulation of Aβ plaques (oligomers) in various areas of the brain 
(Barage & Sonawane, 2015; John & Gerald, 1992) leading, over time, to a number of negative 
effects (Figure 11). For example, neuronal and vascular damage (Haass et al., 2012), toxic 
effects on synapses and mitochondria, altered ionic homeostasis (A. Kumar & Singh, 2015), 
which consequently leads to neuronal dysfunction and eventually cell death (Cell Signalling, 
2009; Haass et al., 2012; Sweatt, 2010).  
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Figure 11 - Schematic representation of APP processing and Aβ accumulation (Imbimbo et al., 2005).  
 
 
 
 
 
 
 
 
 
3.3.3. Transportation and degradation of amyloid-β peptide 
 
Since the first description of the amyloid cascade, the effort has been towards the study 
of Aβ in order to discover a disease modifying therapy to reduce the production or to avoid the 
aggregation of the peptide. Yet, sporadic AD patients don’t show an increase production of this 
peptide.  
Firstly, it has been shown that extracellular Aβ42 can be internalized by neurons, 
followed by the marked generation of Aβ within neurons, which means that extracellular Aβ 
can influence intracellular Aβ and vice versa (Takahashi et al., 2017). In normal human CSF 
and plasma, Aβ40 levels are greater than Aβ42, which is the toxic isoform (Deane et al., 2009). 
However, in the disease state, this equilibrium can be compromised and, consequently, 
leading to an imbalance between Aβ production and clearance, that is determinant for Aβ 
accumulation. Therefore, major efforts have been done to understand the mechanisms behind 
Aβ clearance, since its dysfunction is a crucial step in the disease process (D. S. Wang et al.,  
2006). 
There are three main different pathways responsible for Aβ clearance: receptor-
mediated transport across brain barriers, enzyme-mediated degradation and immunotherapy, 
using anti- Aβ autoantibodies. 
The clearance of Aβ can occur via active transport at the blood-brain barrier (BBB) and 
blood cerebrospinal fluid barrier (BCSFB) (Alemi et al., 2016). This mechanism happens in 
both directions: brain-to-blood, where Aβ binds to many protein, such as, ApoE, ApoJ, 
Transthyretin (TTR) and a soluble form of the low-density lipoprotein receptor-related protein 
1 (sLRP1) (Alemi et al., 2017), located on the cerebral endothelium (Deane et al., 2009), but 
also in the liver and astrocytes (Yoon & Jo, 2012); and blood-to-brain, mediated by RAGE, 
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which is located on the luminal membrane of the endothelium (Y. J. Wang et al., 2006) (Figure 
12). 
Besides that, Aβ can be also degraded by several peptidases, also known as Aβ-
degrading enzymes (ADE), for example, neprilysin (NEP), an enzyme located in the brain, and 
insulin-degrading enzyme (IDE) (Y. J. Wang et al., 2006), either at a single site or at multiple 
sites within Aβ, which produce less neurotoxic and more easily cleared fragments. In fact, 
these ADE were validated in vivo, studies in Tg AD mice model showed a reduction in Aβ 
levels in the brain and improved cognitive function (D. S. Wang et al., 2006; Yoon & Jo, 2012). 
For example, in NEP gene KO in a human APP (hAPP) mouse model, NEP reduction 
contributes to the accumulation of Aβ and impaired hippocampal synaptic plasticity (Huang et 
al., 2006; Madani et al. 2006). 
At last, the immunotherapy, using anti- Aβ autoantibodies has been extensively studied, 
since they have higher specificity for particular antigenic targets, therefore improving the 
selectivity for Aβ (Saido & Leissring 2012) and studies in mouse models of AD have been 
shown a reduced Aβ accumulation (Deane et al., 2009) in CSF, which improved the cognitive 
performance. Nevertheless, this is a mechanism that needs further investigation, since the 
levels of these autoantibodies are very low in the serum (Y. J. Wang et al., 2006). 
To conclude, the equilibrium between the Aβ influx and efflux is important to maintain its 
normal levels in the brain, because if any alterations occur in one of these mechanisms it can 
compromise Aβ clearance and, consequently, leading to all the negative effects described in 
the amyloid cascade hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - Schematic representation of the mechanisms of Aβ clearance. 
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4. AD and DM 
 
In the recent years, new hypothesis and theories regarding AD pathogenesis heavily 
implicate brain insulin resistance as a key factor (Mullins et al., 2017). Hyperinsulinemia and 
insulin resistance, prevalent in T2DM were shown to damage cerebral vasculature and 
increase Aβ accumulation in AD brain (Swaminathan et al., 2017). Besides, in case of insulin 
resistance it can lead to further implications such as inflammation, mitochondrial dysfunction, 
tau and Aβ pathologies (A. et al., 2004; Yin et al., 2016), which are some signs of AD. On the 
other hand, there’s also an association between AD and glucose metabolism/transport, since 
AD patients demonstrate hypometabolism (Khalid Iqbal & Grundke-Iqbal, 2005). Several other 
studies also have shown decreased levels of GLUT1 and 3 and increased levels of GLUT2 in 
the brain of AD patients, thus reducing glucose uptake in the brain (Y. Liu et al., 2008; Mark et 
al., 1997). Importantly, it has been shown that patients with DM have about 65% increased risk 
of developing AD (A. et al., 2004). 
The first clue for this correlation came from a study that showed that Aβ oligomers bind 
to hippocampal neurons triggering the removal of dendritic IRs. Importantly, insulin and IGF-1 
inhibited Aβ production, as well as prevented its intracellular accumulation by promoting the 
transport of Aβ-binding carrier proteins, namely TTR, and increasing the extracellular secretion 
in the brain (Xiaohua Li et al., 2015; Vieira et al., 2015). 
Studies in animal models of diabetes have shown deficits in hippocampal-based memory 
performance, as well as a reduction of hippocampal volume, similar of what happens in AD 
(Kamal et al., 2000; Pennanen et al., 2004). It also has been shown a spatial correlation 
between the distribution of regional glucose metabolism via glycolysis and Aβ deposition, in 
normal adults and AD patients, respectively, which suggests also a link between both diseases 
(Mullins et al., 2017) and an in vitro study demonstrated that the high glucose increased 
significantly the APP levels, consequently, Aβ production (Yang et al., 2013). 
Furthermore, regarding glycolysis, regional lactate production was also linked to Aβ 
levels (Mullins et al., 2017). Lactate, as mentioned before, is one of the glucose products, when 
converted by astrocytes and it is used as an alternate neuronal energy substrate in anaerobic 
conditions (Zawiślak et al., 2017).  
Therefore, although AD is mainly seen as a brain disease it also has alterations in the 
periphery. 
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5. Transthyretin 
5.1. Structure and functions 
 
The protein transthyretin, also known as TTR, was described, in 1942, for the first time 
as “prealbumin”, due to its ability to migrate faster than the albumin on an electrophoresis gel 
of plasma samples (Alshehri et al., 2015), being mainly synthesized by the liver and choroid 
plexus and being secreted into the serum and CSF, respectively (McLean et al., 2017). After  
the first X-ray crystal structure this protein, (human) TTR  was found to be an homotetrameric 
protein, composed of four identical subunits (Richardson, 2007), which originates a ~55 kDa 
protein with 127 amino acids per monomer (McLean et al., 2017). TTR is found in many 
species, since its amino acid sequences or homologous have been determined from species 
like amphibians, reptiles, fish, mammals, which demonstrates a highly conserved structure 
throughout vertebrate evolution (Richardson, 2007).  
TTR is a protein extensively studied, although its catabolism is not fully understood, yet, 
it is known that the liver and kidney are the most active organs of TTR catabolism and its 
internalization is receptor-mediated, for example by megalin, which is expressed in the 
epithelium of renal proximal tubes, and LRP2 (Vieira & Saraiva, 2014). 
The main known physiological role of TTR is the transport of thyroid hormone thyroxine 
(T4) (Gouvea et al., 2013), as well as retinol (vitamin A) that is bound to retinol binding protein 
(RBP) (Berry et al., 2012). Among the three types of free THs, synthetized by thyroid, T4 is the 
most abundant and, in plasma, this hormone binds to three types of transporters, namely 
thyroxin-binding globulin, albumin and, of interest, TTR, which is responsible for transporting 
15% of the hormone. On the other hand, in the CSF, approximately, 80% of the hormone is 
transported by TTR (Vieira & Saraiva, 2014). Despite its role as a transporter and involvement 
in thyroid hormone homeostasis, suggested for a long time, recent studies on TTR null mice 
did not show alterations in T4 or retinol metabolism, suggesting that this protein is not 
necessary for thyroid hormones to be normally distributed (Palha, 2002; Sousa et al., 2005). 
However, is important to highlight, that this strain of mice presents signs of increased anxiety, 
memory and sensorimotor impairment, decreased capacity of regeneration, since TTR plays 
a role in nerves regeneration (Vieira & Saraiva, 2014). 
Furthermore, TTR has been described as a protease, due to its capability of cleaving 
Apolipoprotein A1 (ApoA1), in vivo, and subsequently, impact the cholesterol efflux, by 
reducing it, as observed in cultured cells (Liz et al., 2010; Liz et al., 2004). Moreover, TTR has 
another proteolytic activity, at least in vitro, which is the cleavage of Aβ peptide, suggesting 
that this protein could be involved in the protective mechanism of AD (Liz et al., 2012). Besides, 
NPY was also shown to be cleaved by TTR, according with Liz et al study. All together, these 
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studies suggest that TTR  has natural substrates in the nervous system and might have, that 
remain unknown (Gouvea et al., 2013; Liz et al., 2010). 
Additional data also demonstrates that TTR has neuroprotective effects in other diseases 
from the CNS namely ischemia (Gomes et al., 2016; Santos et al., 2010), nerve regeneration 
(Fleming et al., 2009; Santos et al., 2010) and memory (Sousa et al., 2007). 
 
5.2. TTR as a cause of disease 
 
Regarding the negative conformational changes that TTR can undergo, which means 
being able to change from a normally soluble form to an insoluble fibril, it can be related as 
cause of the most common types of amyloidosis: the senile systemic amyloidosis (SSA) (Ueda 
& Ando, 2014), which is derived from normal-sequence TTR, and familial amyloidotic 
polyneuropathy (FAP) which is derived from variant-TTR sequence (Alshehri et al., 2015). 
FAP, which was described for the first time in 1952, in the north of Portugal (Alshehri et 
al., 2015; Andrade, 1952) and is characterized by misfolded and fibrillary aggregated TTR, 
which most commonly starts with autonomic and peripheral nervous system symptoms, over 
the age of 20, and eventually other organs are affected, as it progresses (Hund, 2012). 
Among the many different pathogenic TTR mutations (Mazzeo et al., 2015), that give 
rise to an heterogeneity of clinical phenotypes, V30M was the first to be identified (Ueda and 
Ando 2014), a substitution of methionine for valine at position 30, but L55P is the most 
aggressive mutation (Sousa & Saraiva, 2003). It is suggested that the disruption of β-structure 
of TTR under such conditions enable self-assembly of the amyloidogenic intermediate and, 
consequently, causing formation of amyloid fibrils (K. Liu et al., 2000). 
 
5.2.1. TTR and DM 
 
Studies on the TTR role in glucose metabolism seem very new and, sometimes, 
controversial. Although only a few studies focused on TTR role in glucose metabolism, in 
T2DM, TTR is found in higher levels (Zemany et al., 2015). In fact, studies in insulin-resistant 
ob/ob mice (leptin-deficient obese diabetic animal model, monogenic, with genetic induced 
obesity or diet induced) have shown elevated levels of serum TTR (Mody et al., 2009), as well 
as high levels of RBP4, indicating that TTR, by preventing the glomerular filtration of RBP, 
contributes to its increased levels and therefore, to disease development (Wei et al., 1995); 
and in some insulin-resistant humans. For instance, a recent study by Xiong et al., evidenced 
elevated levels of TTR in pregnant women, which, consequently, leads to GDM (Xiong et al., 
2017).  
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On the other hand, in T1DM TTR levels were found to be decreased (Itoh et al., 1992). 
A recent study showed that TTR KO mice show impaired recovery of blood glucose and 
glucagon levels, suggesting that TTR may have an important role in glucose homeostasis (Su 
et al., 2012). However, other study by Marques and co-workers reported no alterations in 
glucose metabolism in TTR KO mice, comparing with WT TTR (Marques et al., 2007). 
However, the effect of insufficient TTR, which would mimic more closely the human situation, 
was not analyzed. 
Furthermore, it also has been shown that TTR promotes insulin release to protect 
pancreatic β-cells against death (Refai et al., 2005) and to bind to glucose-regulated proteins, 
such as Grp78, Grp94, and Grp170, besides the GLUTs, that were previously mentioned. 
These proteins are molecular chaperons of the heat shock protein family, also known as stress 
proteins located in the endoplasmatic reticulum (ER) and induced by oxidative stress, defective 
Ca2+ homeostasis and glucose deprivation  (Dekki et al., 2012). This process facilitates the 
internalization of TTR in pancreatic β-cells, as well as hepatomas cells and astrocytes (Divino 
& Schussler, 1990). 
Moreover, TTR can a be a possible biomarker for dyslipidemia (Zemany et al., 2015). 
Therefore, in a recent study TTR-antisense oligonucleotides (ASO), where shown to decrease 
LDL cholesterol in high-fat diet-fed mice, leading to improvements in insulin-glucose 
homeostasis, such as increased levels of glucose uptake and insulin signaling  (Zemany et al., 
2015). 
Regarding the CNS, TTR expression was shown to be elevated in the dorsomedial 
hypothalamus of rats with exercise-induced anorexia, suggesting a possible role of TTR in the 
modulation of food intake and energy balance, since ICV administration of TTR in normal 
growing rats, decreased NPY levels and, consequently, food intake and body weight (Zheng 
et al., 2016). 
Very recently, neuron-derived TTR has been shown to stimulate glycolytic enzymes of 
astrocytes, such as pyruvate kinase M1/2 isoforms (PKM1/2), which is an enzyme responsible 
for turning glucose into pyruvate, in the glycolysis pathway (Figure 13) suggesting that TTR is 
involved in the formation of the astrocytes glycogen-neuronal mitochondria metabolic pathway 
of energy production, which is required for memory formation (Zawiślak et al., 2017). 
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Figure 13 - Schematic representation of glycolysis pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2. TTR and AD 
 
The main features of AD are the depositions of aggregated Aβ in the brain and 
cerebrovasculature, but because the proportion of aggregation found in extracellular fluid of 
AD patients compared with the proportion found in CSF, serum and in vitro cultures was 
inversely proportional, Schwarzman and his colleagues hypothesized that Aβ was sequestered 
by extracellular protein, being the first group to find a relation between  TTR and Aβ, showing 
that TTR is the major sequestering protein in CSF, suggesting that TTR could have a 
neuroprotective role in AD (Schwarzman et al., 1994). Therefore, several studies have been 
done, throughout the years, in order to understand this relationship. In fact, this was 
corroborated by the observation of AD patients brains where TTR levels where decreased in 
CSF (Gloeckner et al., 2008). Importantly, TTR levels correlate with disease state, meaning 
that TTR could be a biomarker (Gloeckner et al., 2008). 
Studies in vivo obtained from AD transgenic mice established in different TTR genetic 
backgrounds demonstrated that the genetic reduction of TTR resulted in increased Aβ 
clearance and total Aβ brain levels (Buxbaum et al., 2008; Costa et al., 2008). 
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In previous study, Costa et al. (2008) observed that variants of TTR bind differently to 
Aβ peptide. For example, L55P TTR, which is the less stable and most amyloidogenic, had 
less affinity to bind do Aβ. On the contrary, T119M TTR showed the highest affinity among all 
tested. Because T119M TTR is the non-amyloidogenic variant known to attenuate the 
symptoms of FAP patients, it is suggested that the conformational molecular changes are 
important to the binding to Aβ and thereby its clearance (Costa et al., 2008). 
Furthermore, Alemi et al. (2016), using an in vitro BBB model, human cerebral 
microvascular endothelial cell line (hCMEC/D3), also observed Aβ efflux promoted by TTR at 
the BBB, but only in the brain-to-blood direction, indicating that TTR is only responsible for the 
removal of the peptide from the brain and not for his entry back into the brain, corroborating 
the neuroprotective role of TTR in AD (Alemi et al., 2016). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Objectives 
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Although some reports attribute some roles to TTR in glucose metabolism, the underlying 
mechanism(s) are not completely known. Additionally, if and how this function relates to the 
neuroprotective role of TTR in AD, is also not understood.  
Thus, this project aimed at clarifying the mechanisms by which TTR is involved in 
glucose metabolism, both at the liver and brain, and at providing some clues on how this might 
be important in AD. 
Therefore, to pursue with this project, the following experiments were performed: 
 
1. Measurement of glucose levels in different cellular models with different levels of TTR, to 
assess TTR effect on glucose levels: 
1.1. In plasma of mice with different TTR genetic backgrounds (TTR+/+, TTR+/- and TTR-
/-), under fasting conditions. 
1.2. In media of primary hepatocytes derived from TTR+/+, TTR+/- and TTR-/- mice. 
1.3. In media of HepG2 cells treated and non-treated with TTR. 
1.4. In media of hCMEC/D3 cells treated and non-treated with TTR. 
 
2. Measurement of TTR levels under different concentrations of glucose, to assess effect of 
glucose on TTR levels: 
2.1. In culture media of primary hepatocytes (TTR+/+ or TTR+/-) treated with different 
concentrations of glucose. 
 
3. Investigation of the effect of TTR on glucose transporters by measuring levels of GLUT1 
in: 
3.1. Primary hepatocytes derived from TTR+/+, TTR+/- and TTR-/- mice and in TTR-/- 
hepatocytes treated with TTR. 
3.2. HepG2 cell line treated with or without TTR. 
3.3. hCMEC/D3 cells treated with or without TTR. 
3.4. In brains and livers of mice TTR+/+, TTR+/- and TTR-/-. 
 
4. Address the impact of TTR involvement in glucose metabolism in the context of glucose 
signaling cascade by assessing the effect of TTR in the gene expression of PKM1/2 at the 
transcript level using the qRT-PCR approach, in hCMEC/D3 and HepG2 cell lines. 
 
5. Measurement of the levels of glucose in the absence or presence of Aβ in primary 
hepatocytes derived from mice with different TTR backgrounds, to link TTR, glucose 
metabolism and AD. 
  
 
 
 
 
 
 
 
 
 
 
 
Material and Methods  
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1. Human recombinant TTR production 
 
Escherichia coli BL21 was used as a bacterial expression system to produce Human 
recombinant TTR (hTTR), using pET plasmids (Furuya et al., 1991) and the purification was 
performed as previously described (Almeida et al. 1997). In general, after growing the bacteria, 
the protein of interest was isolated and purified by ion-exchange chromatography and isolated 
afterwards, through gel electrophoresis. The protein concentration was determined using the 
Bradford Method (Bio-Rad), using bovine serum albumin (BSA) as standard. 
 
2. Animals 
 
The model used for this purpose was a mouse model (SV129 background) with different 
backgrounds of TTR: TTR-wild type (TTR+/+), TTR-heterozygous as a model for TTR 
insufficiency (TTR+/-) and TTR-Knock out as a model for TTR deficiency (TTR-/-). Animals 
were housed in a controlled environment (12h light/dark cycles, temperature between 22-24 
ºC, humidity between 45-65% and 15-20 air changes/hour), with freely available food and 
water.  
Furthermore, all these procedures were done with extreme caution and always taking 
into account the less or absence of pain and stress in the animal; all animals experiments were 
carried out in accordance with the European Communities Council Directive, as well as the 
recommendations of the Federation for Laboratory Animal Science Association (FELASA) and 
approved by the National Authority for Animal Health (DGAV; Lisbon, Portugal). 
 
3. Blood and organ collection 
 
After 7h of fasting - in which mice are deprived of food during 7h in the day, but have 
access to water - mice were anesthetized with a mix of anesthetics (Ketamine 75 mg/kg and 
Medetomidine 1 mg/kg) intraperitoneally (IP) and after evaluating the anesthetic depth by 
caudal and paw withdrawal reflexes, mice were cut in the skin and subcutaneous tissues, the 
intestine and liver were displaced and blood was collected from vena cava with syringes with 
EDTA (as an anticoagulant), in order to obtain plasma, which was followed by centrifugation 
at 14000 rpm for 10 min at 4 ºC. Plasma were collected and frozen at -80 ºC until used. 
Then, a catheter cannula was inserted in the heart of the animal, specifically in the 
ventricular zone, then the inner needle of the cannula was removed and the connected 
peristaltic pump was turned on, letting the perfusion medium, which was PBS at 37 °C, perfuse 
through the heart to the whole body, in order to eliminate any traces of blood in the tissues, 
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and then the right atrium was immediately cut. After 4 minutes of perfusion, the liver, kidneys 
and brain were carefully collected. The brains were bisected longitudinally and fixed for 24h at 
4 ºC in 10% formalin. Then, they were washed with PBS and finally transferred to a 30% 
sucrose solution for cryoprotection before cryostat sectioning and immunohistochemical 
analyses. 
 
4. Immunohistochemistry 
 
To investigate GLUT1 expression in brains from mice under fasting conditions, 30 μm-
thick coronal brain sections of mice were washed with PBS and dried O/N at RT on APES-
precoated slides. Then, sections were permeabilized with 0.25% Triton X-100 in PBS for 10 
min at RT, blocked with 5% BSA in PBS for 1h at RT and incubated with primary antibody 
mouse GLUT1 (1:400, Abcam) in 1% BSA in PBS overnight at 4 ºC. Next, sections were 
washed with PBS and incubated with Alexa Fluor-488 donkey anti-rabbit IgG antibody (1:2000) 
for 1h at RT. To remove tissue autofluorescence, Sudan Black B solution (0.3% Sudan Black 
B in 70% ethanol) was applied for 5 min at RT, followed by washing one time with water and 
after 8 times with PBS. Then, brain sections were mounted with FluoroshieldTM with DAPI 
(Sigma-Aldrich) and visualization was done with the Zeiss Axio Imager Z1 microscope 
equipped with an Axiocam MR3.0 camera and Axivision 4.9.1 software.  
 
5. Human cell lines and primary cultures of mouse hepatocytes 
 
Two different cell lines were used, one as a BBB model: immortalized human cerebral 
microvascular endothelial cell line (hCMEC/D3 cell line), purchased at Tebu-Bio, and the other 
one as a model of the liver: immortalized human liver carcinoma cell line (HepG2 cell line), 
available in the lab. Both cell types were cultured according to the available cell line data sheet. 
hCMEC/D3, used between passages (25-35), were seeded in flasks or plates coated 
with rat tail collagen type I (Sigma) at a concentration of 150 µg/mL during 2h at 37º C or O/N. 
The growing medium for hCMEC/D3 consists of EBM-2 medium (Lonza) supplemented with 
5% Fetal Bovine Serum (FBS) (Gibco), 1% Penicillin-Streptomycin (Lonza), 1.4 µM of 
Hydrocortisone (Sigma), 5 µg/mL of Acid Ascorbic (Sigma), 1% of Chemically Defined Lipid 
Concentrate (Gibco), 10 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
(Gibco) and 1 ng/mL of bFGF (Sigma). 
HepG2 cells were used between passages 21 and 24, seeded in flasks or plates with no 
coating surfaces, were grown in Dulbecco’s Modified Eagle Medium (DMEM) (1x) (Lonza) and 
Ham’s F-12 media (Gibco), supplemented with 10% FBS (Gibco), 100 U/mL penicillin-
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streptomycin (Gibco), 2 mM L-Glutamine (Gibco) and 1x Non-essential amino acid solution 
(Lonza). 
To obtain the primary hepatocytes, firstly, the liver was perfused, that is, the abdomen 
was opened, the organs displaced and the vena cava and portal vein were detected. Then, a 
catheter cannula was inserted inside the portal vein and wash perfusion medium (HBSS 1x 
medium containing 0.025 M HEPES and 2 mM EDTA) was allowed to perfuse through the 
liver, for 10 min and the vena cava was cut immediately. After that time, the perfusion medium 
was changed to digestion medium containing collagenase type V ((Williams E medium (WE, 
Gibco), containing 10% FBS, 3 mM CaCl2, 0.01 M HEPES and 0.25 mg/mL Collagenase type 
V (sigma-Aldrich)) for another 10 minutes. At the end, the liver was removed to a Petri dish 
containing isolation medium (WE medium containing 10% FBS, 2 mM EDTA and 0.01 M 
HEPES), ready to proceed to the next steps: centrifugation, counting live cells and seeding 
cells, with attachment media (WE medium containing 10% FBS and 0.01 M HEPES) for 3 h. 
After 3h, the cells were washed with warm PBS so that unattached cells dissociate and 
incubated with stimulation medium, containing 2x penicillin-streptomycin, 0.01 M HEPES, 
0.04% Fungizone, 0.05 mM Dexamethazone, 1 µM Insulin and 0.05 M 2 Mercapto-ethanol. 
After 24h, the cells were washed again with warm PBS and new stimulation medium was 
added. After 48h, the experiments were performed. 
 
6. Protein Extraction 
 
Proteins from hCMEC/D3, HepG2 and primary hepatocytes cells were extracted in lysis 
buffer (20 mM MOPS pH 7.0, 2 mM EGTA; 5 mM EDTA, 30 mM sodium fluoride, 60 mM β -
glycerophosphate pH 7.2, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1% 
triton X-100) by doing up and down with the pipette, followed by incubation for 20 min on ice. 
Then, the extracts were centrifuged at 14000 rpm for 20 min, at 4º C, and the supernatants 
were collected and further used for protein analysis. The total protein concentration was 
quantified in all extracts by the Bradford Method (Bio-Rad), using BSA as standard. 
 
7. Glucose measurement in mice plasmas and supernatant media of 
primary hepatocytes 
 
Glucose levels in plasmas (mg/dL) from fasted mice and in supernatants from cultures 
of primary hepatocytes, previously incubated for 24h, with or without additional exogenous 
hTTR (0.5 µM), as well as supernatants from cultures of hCMEC/D3 and HepG2 cells, 
previously incubated for 7h, with or without additional exogenous hTTR (0.2 µM and 0.5 µM), 
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were measured using a glucose assay kit (Abcam) following the manufacturer’s instructions. 
Proteins from cells were also extracted, quantified by Bradford and used to normalize the levels 
of glucose in the supernatants. Results are expressed as glucose levels (mg/dL) per mg of 
protein.  
 
8. Quantification of mouse TTR by ELISA 
 
Mouse TTR in the supernatants of primary cultures of hepatocytes derived from TTR+/+ 
and TTR+/- mice, control or treated with glucose (20 mM and 35 mM, for 1h, 6h and 24h), were 
quantified using Mouse Prealbumin ELISA Kit (MyBioSource) according to the manufacturer’s 
instructions. Data were expressed in mg/L. 
 
9. Immunocytochemistry 
 
hCMEC/D3 and HepG2 cells were grown on glass coverslips (Thermo Fisher Scientific) 
previously autoclaved. Cells were grown until reach 80% of confluence and then incubated 
with their respective media in the absence or presence of TTR variants. 
To study GLUTs levels, in particular GLUT1, hCMEC/D3 were incubated with 0 µM; 0.2 
µM; 0.5 µM of hTTR for 7h. To study GLUT1, HepG2 cells were incubated with the same 
concentrations of hTTR, for 30 min, 1h and 7h. Then, cells were washed 3 times with PBS and 
fixed with acetone for 7 min at RT. Following fixation, cells were washed again 3 times with 
PBS, the last wash for 5 min at RT. Next, blocking was performed with 5% BSA in PBS for 1h, 
followed by incubation with primary antibody mouse GLUT1 (1:33.3, Abcam), O/N, at 4º C. 
After being washed 3 times with PBS for 5 min each, cells were incubated with the Alexa Fluor-
488 anti-mouse IgG antibody (Invitrogen 1:2000) for 1h at RT. Coverslips were mounted with 
FluoroshieldTM with DAPI (Sigma-Aldrich) and visualization was done with Zeiss Axio Imager 
Z1 microscope. The images visualization were performed with Axiovision 4.9.1 software and 
quantification was done using ImageJ software. 
 
10. Western Blot (WB) analysis 
 
The expression of glucose transporter GLUT1 in hCMEC/D3, HepG2 cells and primary 
hepatocytes were studied by Western Blot (WB) analysis. 
Protein extract samples (50 µg), partially denatured after 15min incubations at 37 ºC, 
were separated (amperage of 20 mA) in 10% SDS-PAGE gels. Then, the proteins were 
transferred for 90 min (voltage of 100 V and 400 mA) to nitrocellulose membrane, previously 
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treated with distillated H2O (dH2O) (15 min) and Transfer Buffer (10 min), using a wet system 
(Bio-Rad Criterion Blotter). Then, the membranes were dyed with Ponceau, washed with dH2O, 
followed by PBS containing 0.05% Tween-20 (PBS-T) and blocked 1h at RT with 5% of milk 
in PBS-T. After blocking, membranes were incubated with primary antibody against mouse 
GLUT1 (1:500 / 54 kDa, Abcam) overnight at 4 ºC, or with antibody against mouse β-actin 
(1:5000 / 47 kDa, Sigma) as reference protein, for 1h at RT in 3% milk/PBS-T. Then, after 
three washes in PBS-T, membranes were incubated 1h at RT with anti-mouse HRP (1:2500) 
in 3% milk/PBS-T. The blots were developed using Clarity™ Western ECL substrate (Bio-Rad) 
and proteins were detected and visualized using chemiluminescence detection system 
(ChemiDoc, Bio-Rad). When necessary, membranes were stripped for 10 min at RT with, also, 
gentle shaking, using commercial stripping buffer (Restore™ Western Blot stripping buffer; 
Thermo scientific) for re-utilization of the membranes, according to the manufacturer’s 
instructions. 
 
11. Gene expression- qRT-PCR 
 
For the Real-Time Polymerase Chain Reaction (qRT-PCR) analysis, hCMEC/D3 and 
HepG2 cell lines were used and incubated in the presence or absence of hTTR (0.5 µM) for 
16h (O/N) and total RNA was then isolated from cells using Trizol reagent (Invitrogen) following 
the instructions available in the product datasheet. RNA concentration and purity were 
quantified by reading the absorbance at 260 nm and the A260/A280 ratio, respectively, with 
NanoDrop photometer (Thermo Fisher Scientific), and RNA integrity was determined by 
Experion. For qRT-PCR, the primers were designed, according to their sequence available in 
the National Center for Biotechnology Information (NCBI) and using the functionality Beacon 
Designer 7 provided by CCGene lab from i3S described in Table 2. Human β-actin was used 
as an internal control for normalization. The reaction mix was done with iTaq SYBR green (iQ 
SYBR green supermix, BioRad) following the manufacturer’s instructions. PCR primers and 
conditions used for all analyzed genes are also shown in Table 2. The qRT-PCR was 
performed using the iQ5 BioRad Detection System (BioRad). The relative quantification was 
performed according to the comparative method (2-ΔΔct). 
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Table 2. Sequences of the “in-house designed” primers. PCR condition was the same for all primers.  
Gene Primer Sequence PCR Condition 
 
Human 
PKM1/2 
 
 
Forward:5’ CAGCCAAAGGGACTATCCT 3’ 
Reverse: 5’ GAGGCTCGCACAAGTTCTTC 3’ 
Initial denaturation: 
95ºC, 3 minutes 
 
Denaturation, 
annealing and 
extension (40 
cycles): 
95ºC, 15 seconds 
60ºC, 30 seconds 
Human 
β-actin 
Forward: 5’ CCAACCGCGAGAAGATGA 3’ 
Reverse: 5’ TCCATCACGATGCCAGTG 3’ 
 
12. Statistical analysis 
 
Data following a Gaussian distribution, was analyzed by one-way ANOVA and the 
comparisons between groups made with Student’s t-test, when p values lower than 0.05, they 
were considered statistically significant. All data was expressed as mean±SEM. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Results  
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Figure 14 - Plasma glucose levels (mg/dL) in fasted mice, illustrating the higher glucose levels in plasma from TTR+/- 
mice as compared to TTR+/+ and TTR-/- animals (n=4 for TTR+/+; n=11 for TTR+/-; n=7 for TTR-/-). Data are expressed 
as mean ±SEM. p< 0,05 (*). 
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1. TTR affects glucose levels 
1.1. Insufficient TTR in plasma of mice with only one copy of the TTR gene 
presents elevated glucose levels  
 
As previously described, TTR is found in higher levels in plasma of T2DM and in lower 
levels in T1DM and in the plasma and CSF of AD patients. To assess the influence of TTR on 
the regulation of glucose metabolism, as a first approach, we measured the glucose levels in 
mice plasma with different backgrounds of TTR, under fasting conditions.  
As it can be seen in Figure 14, mice with insufficient TTR (TTR+/-) showed increased 
plasma glucose levels. However, mice deficient in TTR (TTR-/-) showed no significant 
differences compared to TTR+/+ mice, confirming previous results reported by Marques and 
co-workers (Marques et al., 2007), which may be explained by compensation mechanisms 
developed to overcome the total absence of TTR, at all stages of develoment of the animals. 
 
 
 
 
 
 
 
 
1.2 . Insufficient TTR results in elevated levels of glucose in the media of 
cultured h patocytes 
 
Given the importance of the liver, as described in the introduction, being the major site 
of production and catabolism of TTR, as well as the main responsible organ in the maintenance 
of normal glucose homeostasis of the body, we then analyzed the glucose levels in supernatant 
of hepatoma cells (HepG2) incubated in the absence or presence of hTTR. 
As depicted in Figure 15 (A), there are no alterations in the glucose levels in the 
supernatants of HepG2 cells incubated in the absence of hTTR, which could be due to the fact 
that cell lines, sometimes, don’t reproduce the phenotype observed in vivo.  
Therefore, and aiming at bringing the model closer to the in vivo situation, we analyzed 
the same parameters in primary hepatocytes derived from mice with different TTR genetic 
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Figure 15 - Glucose levels (mg/dL) in the supernatants of cultured hepatocytes, normalized by mg of protein. (A) In HepG2 
cells, the presence or absence of hTTR (0.2 and 0.5 µM) did not alter the levels of glucose (n=5 for each condition). (B) 
Supernatants from primary hepatocytes derived from TTR+/- and from TTR-/- mice presented higher glucose levels, 
compared to those from TTR+/+; addition of hTTR (0.5 µM) only rescued the phenotype from TTR+/- cultures, resulting 
in decreased glucose concentration (n=3 for each condition). Data are expressed as mean ±SEM. p< 0,05 (*); p<0,0001 
(****). 
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backgrounds. The results are displayed in Figure 15 (B) and confirm that insufficient TTR in 
TTR+/- mice significantly increased the glucose levels in supernatant of primary hepatocytes. 
Further, addition of hTTR (0.5 µM) to the media of the TTR+/- primary hepatocytes, partially 
rescued the phenotype and significantly decreased the glucose levels. We also observed that 
glucose in the supernatants of TTR-/- hepatocytes was higher than in the TTR+/+, differently 
from the measurements in plasmas. Nevertheless, these levels were lower than in the TTR+/- 
cultures and, importantly, addition of hTTR did not alter glucose concentration, again indicating 
that other mechanisms are activated. 
 
 
 
 
 
 
 
 
  
 
1.3.  Insufficient TTR results in elevated levels of glucose in the media of a 
BBB cellular model 
 
Furthermore, regarding the constant need of the brain to be supplied with glucose 
through the BBB, which is used to transduce energy through glycolysis and mitochondrial 
oxidative phosphorylation to support synaptic transmission (Yin et al., 2016), we also 
investigated the effect of TTR in glucose levels in the BBB model used in our study (the 
hCMEC/D3 cell line).  
For that, glucose levels were measured in the media of hCMEC/D3 cells, incubated in 
the absence or pr sence of hTTR (0.2 µM and 0.5 µM). As presented in Figure 16, result show 
a significant decrease in glucose levels in the supernatant of these cells in the presence of 
hTTR.  
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Figure 16 - Glucose levels (mg/dL) in the supernatants of cultured hCMEC/D3, normalized by mg of total protein, showing 
that the presence of hTTR (0.5 µM) significantly decreased the concentration of glucose in the media (n=3 for each 
condition). Data are expressed as mean ±SEM. p< 0,05 (*). 
 
 
 
 
 
 
 
Figure 17 - Analysis of TTR in the supernatants of cultured primary hepatocytes derived from TTR+/+ or TTR+/-, showing 
that different glucose concentrations (20 mM and 35 mM at 1h, 6h and 24h) did not affect the levels of this protein. Data 
are expressed as mean ±SEM. p< 0,05 (*) 
 
 
 
 
 
 
 
 
Figure 18 - Analysis of protein expression in HepG2 cells without or with incubation of TTR. (A) Immunofluorescence 
analysis of GLUT-1 expression in HepG2 cells stained with an antibody against each protein (green). Nucleus of cells are 
stained with DAPI (blue). (B) Statistical analysis of immunocytochemistry p<0,05 (*). (C) Western Blot analysis for GLUT-
1 expression in the absence or presence of hTTR.(D) Statistical analysis for Western Blot p<0,05 (*). 
 
Figure 17 - Analysis of TTR levels under different glucose concentrations 20 mM and 35 mM in 1h, 6h and 24h in primary 
hepatocytes. 
 
 
 
 
 
Taken together, our results suggest that insufficiency of TTR impairs glucose 
metabolism, both in the periphery and at the BBB. 
 
 
 
 
 
 
 
 
2. Glucose does not affect TTR expression in primary hepatocytes 
To understand if the observed decreased glucose metabolism was a consequence or a 
cause of the TTR insufficiency, we evaluated the effect of different concentrations of glucose 
in TTR levels. For that, we incubated primary hepatocytes derived from TTR+/+ and TTR+/- 
mice, with different glucose concentrations (11.11 mM (Ctrl media), 20 mM and 35 mM) at 
three different time-points (1h, 6h and 24h) and measured the levels of TTR by ELISA. Our 
results showed no alterations in the TTR levels for any of the glucose concentrations, in any 
of the incubation times (Figure 17), which indicates that glucose alterations do not precede 
TTR insufficiency, but instead, probably it is the other way around: alterations in TTR are prior 
to the changes in glucose levels. 
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Figure 17 - Analysis of TTR in the supernatants of cultured primary hepatocytes derived from TTR+/+ or TTR+/- mice, 
showing that different glucose concentrations (11.11 mM (Ctrl), 20 mM and 35 mM at 1h, 6h and 24h) did not affect the 
levels of this protein (n=2 for each condition). Data are expressed as mean ±SEM. 
 
 
 
 
 
 
 
 
Figure 18 - Analysis of protein expression in HepG2 cells without or with incubation of TTR. (A) Immunofluorescence 
analysis of GLUT-1 expression in HepG2 cells stained with an antibody against each protein (green). Nucleus of cells are 
stained with DAPI (blue). (B) Statistical analysis of immunocytochemistry p<0,05 (*). (C) Western Blot analysis for GLUT-
1 expression in the absence or presence of hTTR.(D) Statistical analysis for Western Blot p<0,05 (*). 
 
Figure 17 - Analysis of TTR levels under different glucose concentrations 20 mM and 35 mM in 1h, 6h and 24h in primary 
hepatocytes. 
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3. Transthyretin modulates the expression of GLUT1: 
3.1. In liver models 
 
A previous study demonstrated that TTR binds to glucose-regulated proteins (Dekki et 
al., 2012) and glucose transporters are the main family mediating glucose uptake in tissues. 
Since GLUT1 is expressed in most cells, in the case of hepatocytes it is mainly expressed on 
the sinusoidal membrane, and is responsible for basal glucose uptake, therefore we decided 
to investigate the effect of TTR on this glucose transporter in the liv rs of mice with different
TTR background  by immunohistochemistry. However, we could n draw conclusions from 
those experiments, since the primary antibody used produced nonspecific binding.  
To partially overcome this drawback, we proceeded to immunocytochemistry analysis 
using HepG2 cells, incubated in the absence or presence of hTTR and our results showed a 
significant increase in GLUT1 expression in the presence of hTTR, after O/N incubation 
(Figure 18 (A)). To corroborate these results, we also performed a WB, and despite the images 
are technically not very good, a significant increase in GLUT1 expression was observed in the 
presence of hTTR (Figure 18 (B)). 
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Figure 18 - Analysis of GLUT1 expression in HepG2 cells without or with incubation with hTTR (0.5 µM). (A) 
Immunofluorescence analysis of GLUT1 expression in HepG2 cells stained with an antibody against the protein (green). 
Nucleus of cells are stained with DAPI (blue). (B) WB analysis for GLUT1 expression in the absence or presence of hTTR 
(0.2 µM) (n=7 for each condition). Data are expressed as mean ±SEM. p< 0,05 (*). 
 
 
 
 
Figure 18 - Analysis of protein expression in HepG2 cells without or with incubation of TTR. (A) Immunofluorescence 
analysis of GLUT-1 expression in HepG2 cells stained with an antibody against each protein (green). Nucleus of cells are 
stained with DAPI (blue). (B) Statistical analysis of immunocytochemistry p<0,05 (*). (C) Western Blot analysis for GLUT-
1 expression in the absence or presence of hTTR.(D) Statistical analysis for Western Blot p<0,05 (*). 
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Figure 19 - Analysis of GLUT1 expression in primary hepatocytes cells without or with incubation of hTTR (0.5 µM) O/N.   
Immunofluorescence analysis of GLUT1 and expression in primary hepatocytes cells stained with an antibody against 
the protein (green). Nucleus of cells are stained with DAPI (blue) (n=8 for each condition). Data are expressed as mean 
±SEM. 
0.5 µM hTTR 
Ctrl 
 
Also, GLUT1 levels in primary hepatocytes from TTR+/+ and TTR-/- mice were analyzed. 
TTR+/+ hepatocytes and TTR-/- hepatocytes treated with hTTR (0.5 µM) to the TTR-/- showed 
a trend for increased GLUT1 expression compared to TTR-/- hepatocytes incubated with no 
hTTR (Figure 19). The lack of statistical significance may be related to the low number of 
replicas. 
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Figure 20 - Analysis of protein expression in hCMEC/D3 without or with incubation of hTTR (0.2 and 0.5 µM). 
Immunofluorescence analysis of GLUT1 expression in hCMEC/D3 stained with an antibody against each protein (green). 
Nucleus of cells are stained with DAPI (blue) (n= 7 for each condition). Data are expressed as mean ±SEM.  
 
 
Figure 20 - Analysis of protein expression in HepG2 cells without or with incubation of TTR. (A) Immunofluorescence 
analysis of GLUT-1 expression in hCMEC/D3 cells stained with an antibody against each protein (green). Nucleus of cells 
are stained with DAPI (blue). Data are expressed as mean ±SEM.  
 
 
Figure 20 - Analysis of protein expression in HepG2 cells without or with incubation of TTR. (A) Immunofluorescence 
analysis of GLUT-1 expression in hCMEC/D3 cells stained with an antibody against each protein (green). Nucleus of cells 
3.2. In the BBB model 
 
GLUT1 is the major glucose transporter in the BBB, providing a homeostatic control for 
glucose into the brain by preventing glucose accumulation in the brain interstitial fluid (Zlokovic, 
2008). Thus, we also investigated the expression of this transporter in mice brains by 
immunohistochemistry, but again, we encountered technical problems related to the primary 
antibody. 
Therefore, we proceeded again to immunocytochemistry analysis, using hCMEC/D3 
incubated in the absence or presence of hTTR (0.5 µM) for 7 hours. Our results showed no 
significant difference in the expression of GLUT1 by hCMEC/D3, under the experimental 
conditions, and contrarily to the liver models, the presence of hTTR tended to induce a 
decrease in GLUT1 (Figure 20).  
Our results are not in concordance with previous studies that have shown that brain 
glucose uptake correlates with GLUT1 levels at the BBB (Zeller et al., 1997), so we questioned 
what other mechanism involved in glucose transport at the BBB could be affected by TTR and 
explain the lower glucose levels in the supernatants of hCMEC/D3 TTR-treated cells. 
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Figure 21 - qRT-PCR analysis of PKM gene at the transcript levels in a BBB and hepatocyte cell line models without or 
with incubation of hTTR (0.5 µM). (A) hCMEC/D3 and (B) HepG2 cells data are expressed as mean ±SEM (n=3 for each 
condition). 
 
 
 
 
Figure 21 - qRT-PCR analysis of PKM gene at the transcript levels in a BBB and hepatocyte cell line models without or 
with incubation of TTR. (A) hCMEC/D3 cells statistical analysis ±SEM. (B) HepG2 Statistical analysis ±SEM. 
 
 
4. Impact of TTR involvement in glucose metabolism in the context of 
glucose signaling cascade in the expression of PKM at the transcript 
level 
 
Recently, a study evidenced that neuron-derived TTR stimulates expression of glycolytic 
enzymes, namely pyruvate kinase M1/2 (PKM1/2), in astrocytes (Zawiślak et al., 2017). In 
order to investigate if TTR also affects this pathway in our models, we incubated hCMEC and 
HepG2 cells in the absence or presence of hTTR and performed a qRT-PCR to determine the 
relative gene expression of PKM1/2. 
Our results show a trend for increased expression of PKM in the presence of hTTR in 
hCMEC/D3 (Figure 21 (A)) and the opposite trend in HepG2 cells (Figure 21 (B)), although 
both did not reach the statistical significance  
Altogether, the results referring to the effect of TTR in GLUT1 and in the PKM1/2 gene 
suggest that different mechanisms are influenced by TTR, in different organs. 
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Figure 22 - Analysis of glucose levels (mg) normalized by mg of protein in primary hepatocytes with different 
backgrounds of TTR treated in the absence or presence of Aβ (2 µM) (n=3 for each condition). Data are expressed as 
mean ±SEM. p<0,05 (*); p<0,01 (**). 
5. Effect of Aβ in glucose metabolism at the liver 
 
Finally, to study the link between TTR, glucose metabolism and AD, we incubated primary 
hepatocytes derived from mice with different TTR genetic backgrounds in the absence or 
presence of Aβ (2 µM) and showed that the presence of Aβ significantly increases glucose 
levels in the supernatants of cultures hepatocytes, within each genotype (Figure 22). Further 
studies are necessary to explore these preliminary results. 
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Glucose is an important fuel for our body and mainly for the brain which has to be 
constantly supplied through the BBB to maintain its normal function. This glucose is provided 
through food intake or produced in the liver, a crucial organ that is responsible for the 
maintenance of normal glucose homeostasis, by regulation of glycolysis and gluconeogenesis. 
Transthyretin, also known as prealbumin, is as previously described, a ~55 kDa   
homotetrameric protein, responsible for the transport of the thyroid hormone thyroxine (T4) 
(Gouvea et al., 2013) and retinol, in the blood and CSF (Berry et al., 2012). Throughout the 
years, many studies focused on the neuroprotective role of TTR, including its binding to Aβ 
peptide and impact in AD. Our group has previously shown that TTR promotes Aβ transport 
from the brain to the blood (Alemi et al., 2016) and facilitates its degradation in the liver, 
contributing to its neuroprotective role in AD (Alemi et al., 2017). However, in AD patients TTR 
is found to be decreased in the plasma and CSF (Ribeiro et al., 2012), which can be related to 
the impaired Aβ clearance, attributed to the development of Sporadic AD, which constitutes 
90-95% of all AD cases.  
Recent studies show evidence that abnormalities in glucose transport and insulin 
signaling are associated with AD, since it is reported that patients with DM have about 65% 
increased risk of developing AD (Arvanitakis et al., 2004), and also that AD patients show 
reduced glucose metabolism. For instance, previous studies have shown decreased levels of 
GLUT1 (Mark et al., 1997) and, thus, reduced glucose uptake in the brain (Khalid Iqbal & 
Grundke-Iqbal, 2005).  
Although, the role of TTR in glucose metabolism is still not extensively studied and still 
controversial, according to some studies, TTR is found in higher levels in both T2DM (Zemany 
et al., 2015) and GDM (Xiong et al., 2017), and in lower levels in T1DM (Itoh et al. 1992). 
Besides, TTR was also found to promote insulin release to protect pancreatic cells against 
death (Refai et al., 2005) and its absence can even impair recovery of blood glucose and 
glucagon levels, as shown in a study in TTR KO mice (Su et al., 2012).  
Therefore, this work started by assessing the effect of not only the deficiency but also 
the insufficiency of TTR in glucose metabolism, by measuring mice plasma glucose levels. As 
previously reported by Marques and colleagues (Marques et al., 2007), TTR KO mice did not 
show alterations in the basal or fast-induced circulating levels of glucose, which is in agreement 
with our results, since we did not observe any differences between TTR+/+ and TTR-/- mice. 
However, in our work, differences between TTR+/+ and TTR+/- were evident, as mice with 
insufficient TTR had significantly higher glucose plasma levels. These results indicate that TTR 
is important in the context of glucose metabolism and that insufficient amount of this protein 
impairs uptake of glucose from blood. Also, it is likely that TTR-/- animals activated 
mechanism(s) of compensation, overcoming the absence of TTR. The presence of 
compensation mechanisms related to TTR and AD has been previously reported; AD/TTR+/- 
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but not AD/TTR-/- mice present a more severe form of AD, compared to AD/TTR+/+ (Oliveira 
et al., 2011). In the future, effort should be made to produce and perform studies in conditional 
models, where expression of TTR can be active even before birth and only blocked at a certain 
age, providing a closer model to the human events in AD. 
To gain further insights into the importance of TTR in glucose metabolism, we aimed at 
evaluating this effect both in the brain and at in the liver. As for the liver models, upon 
incubation, primary cultures of TTR+/- hepatocytes showed significantly higher glucose in the 
supernatant, compared to TTR+/+, and addition of hTTR to those cultures, partially rescue the 
phenotype, decreasing the amount of glucose in the supernatant. In this experiments, the TTR-
/- cultures presented glucose levels higher than the TTR+/+ cells (although lower than the 
TTR+/-), indicating that: 1) even primary cultures do not totally reproduce the in vivo events 
and, for instance, these cells may have active mechanism(s), which are inactive in vivo, and/or 
even 2) that plasma glucose is the product of several factors and organs, which are not all 
contemplated in the cellular model, namely the pancreas/insulin system. 
To mimic the BBB, through which glucose can enter into the brain, we used the 
hCMEC/D3 cellular model, showing that increasing the concentration of hTTR, resulted in 
decreased glucose in the supernatant of the cultures. Although we did not assess TTR 
expression by hCMEC/D3 cells, it is important to refer that TTR synthesized by the choroid 
plexus and meninges can be transported to other cells in the brain. For instance, in cases of 
brain ischemia, CSF TTR can control neuronal death and inflammation (Santos et al., 2010), 
meaning that TTR is transported from the CSF to other brain areas via receptor-mediated 
endocytosis (Liz et al., 2010) and, as previously shown, it participates in Aβ clearance (Alemi 
et al., 2017). Further, the confinement of TTR expression in the brain to the choroid plexus 
(and meninges) is controversial, and for instance, it has been shown by quantitative PCR and 
WB, that primary neurons from APP23 mice transcribe TTR mRNA and that these cells 
synthesize and secrete TTR (Xinyi Li & Buxbaum 2011; X. Wang et al., 2014). Another work, 
reports that TTR expression is induced by the APP fragment, AICD, in SH-SY5Y cells, resulting 
in decreased total cellular Aβ levels (Kerridge et al., 2014). 
Because these first results showed a decrease glucose metabolism, a question arose 
whether if this would be a cause or consequence of TTR insufficiency. Aiming to answer this 
question, we evaluated the effect of different concentrations of glucose in TTR levels, and our 
results showed no alterations in TTR levels, indicating that alterations in TTR are prior to the 
changes in glucose levels. 
TTR was found to be able to be internalized by the pancreatic β-cells (Refai et al., 2005) 
and hepatoma cells (Sousa & Saraiva, 2001), which are cells involved in the glucose 
metabolism. Moreover, according to a previous study by Dekki et al., TTR was also found to 
bind to glucose-regulated proteins (Dekki et al., 2012). Regarding these mechanisms and 
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aiming to explain the increased internalization of glucose, in other words the decreased levels 
of glucose in the supernatants and plasma in the presence of TTR, we further investigate the 
mechanism(s) underlying TTR participation in glucose metabolism, by evaluating the 
expression of GLUT1 transporter, which has been described to be expressed on the sinusoidal 
membrane of hepatocytes (Shinoda et al., 2001). Our results showed, as expected, an 
increase in GLUT1 expression in our liver models in the presence of hTTR. In hCMEC/D3, 
however, TTR tend to decrease the GLUT1 expression, suggesting that in these cells there is 
another mechanism involving the decreased levels of glucose in the supernatants of these 
cells. Previous studies, evidenced a down-regulation of GLUT1 in the BBB, besides other 
transporters, in hyperglycemic animals, and they thought that the glycolytic flux could be 
explained by the levels of lactate, which could be influencing other transporters (Duelli et al., 
2000). However, in other studies in hyperglycemic rats, an increase in GLUT1 mRNA 
expression was observed, but no changes were observed in the glucose transport (Simpson 
et al. 1999), which makes it controversial, and further insight in this correlation GLUT-glucose 
at the BBB should be investigated.  
Regarding the CNS, TTR was described to be involved in cognition, behavior (Sousa et 
al., 2004), neuropeptide maturation (Nunes et al., 2006), nerve regeneration (Fleming et al., 
2009; Fleming et al., 2007; Groop & Pociot, 2014) and in ischemia (Santos et al., 2010) but 
most importantly, in a recent study neuron-derived transthyretin (TTR) was shown to stimulates 
expression of glycolytic enzymes, namely pyruvate kinase M1/2 (PKM1/2), in astrocytes 
(Zawiślak et al., 2017), which provides energy required for memory formation. In order to 
confirm what mechanism could be involved in the BBB cell model, and to investigate the effect 
of TTR in downstream pathways of glucose signaling cascade, we determined the relative 
gene expression of PKM in the absence and presence of hTTR, using hCMEC/D3 and HepG2 
cell lines. Here we showed that PKM1/2 tended to increase in the presence of hTTR in 
hCMEC/D3, which could explain the decreased glucose levels, in spite of the observed 
decrease in GLUT1. In the HepG2 cells, however, we saw the opposite trend, PKM1/2 tended 
to decrease in these cells, in spite of the observed increase expression of GLUT1, suggesting 
that TTR modulates differently the liver and the BBB. 
To further link TTR, glucose metabolism and AD, we evaluated glucose levels in the 
presence of Aβ peptide, using primary hepatocytes. Aβ deposition is found to induce lipid 
peroxidation, which has been demonstrated to decrease glucose transport and metabolism in 
hippocampal and cortical neurons (Mark et al., 1997). Besides, Aβ deposition can also cause 
disruption of ion homeostasis and apoptosis (Mark et al., 1997). Importantly, IGF-1 was found 
to influence Aβ clearance from the brain, by promoting Aβ transport across the BBB (Freude 
et al., 2009) but Aβ can also compete with insulin transporters, affecting insulin response to 
high glucose levels. In our results, we saw an increase of glucose levels in the supernatants 
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of cultures hepatocytes in the presence of Aβ within each genotypes (TTR+/+; TTR+/- and 
TTR-/-), but further studies are necessary to explore these preliminary results. 
Altogether, our results indicate that TTR is involved in glucose metabolism and 
modulates both the BBB and the periphery. Regarding the levels of glucose in the plasma, and 
in the supernatants of BBB and liver cells, TTR decreased those levels, suggesting that TTR 
influences the internalization of glucose, but probably through different mechanisms. On one 
hand, in the BBB, TTR decreased GLUT1 expression, but increased PKM1/2 expression, 
which can be the reason behind the decrease in glucose levels in the supernatants, suggesting 
TTR may act downstream in the glucose cascade signaling. On the other hand, in the HepG2 
cells, TTR increased the levels of GLUT1 expression, and decreased the PKM1/2 levels, which 
suggests that TTR may affect more significantly on upstream proteins such as glucose 
transporters.  
In the future, it would be interesting to perform an experiment using the hCMEC/D3 cells 
cultured in transwell inserts, inducing the BBB polarity, in order to understand TTR effect on 
GLUT1 levels on each side of the BBB and thus explain the observed increased glucose 
uptake in the presence of TTR. Besides, in order to address the downstream pathways of 
glucose metabolism, by qRT-PCR, instead of using only hCMEC/D3 cell line, as used in our 
work, primary cultures, namely cerebral endothelial cells, astrocytes or neurons, could be also 
used for a more detailed insight. 
As for the upstream pathways of glucose signaling cascade, it would be interesting to 
study the other glucose transporters present in the liver, as well as the effect of TTR on insulin 
expression.  
Furthermore, although our mouse model was already established with different 
backgrounds of TTR, it would be interesting to know the effect of TTR, by silencing the 2 copies 
of TTR gene expression in TTR+/+, instead of reproducing mice born already with no TTR. 
Overall, our results have shown that TTR 1) influences the internalization of glucose, 
through 2) modulation of upstream proteins in the liver, such as glucose transporters and 
possibly 3) modulation of downstream pathways in the BBB. These results provide relevant 
information for TTR-based therapeutic strategies for AD, since TTR role in glucose metabolism 
seems to be neuroprotective. Alterations in glucose metabolism are thought to be related to 
AD and thus this work highlights the potential role of TTR as a protective protein and as a 
therapeutic target. 
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